Results overview: Found 9 records in 0.01 seconds.
Articles, 9 records found
Articles 9 records found  
1.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital) ; Ciuleanu, Tudor (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; Garcia-Carbonero, Rocio (University Hospital Virgen del Rocío) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven - KU Leuven) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO Open, Vol. 3 (april 2018)  
2.
19 p, 418.6 KB Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study / Van Cutsem, Eric (University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ; Huijberts, Sanne (Netherlands Cancer Institute, Amsterdam, the Netherlands) ; Grothey, Axel (West Cancer Center, Germantown, TN) ; Yaeger, Rona (Memorial Sloan Kettering Cancer Center, New York, NY) ; Cuyle, Pieter-Jan (Imelda General Hospital, Bonheiden, Belgium; University Hospitals Gasthuisberg, Leuven, Belgium) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Fakih, Marwan (City of Hope Comprehensive Cancer Center, Duarte, CA) ; Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ; Peeters, Marc (Antwerp University Hospital, Edegem, Belgium) ; Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Wasan, Harpreet (Hammersmith Hospital, Imperial College London, London, United Kingdom) ; Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ; Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli," Naples, Italy) ; Gollerkeri, Ashwin (Array BioPharma Inc, Boulder, CO) ; Christy-Bittel, Janna (Array BioPharma Inc, Boulder, CO) ; Maharry, Kati (Array BioPharma Inc, Boulder, CO) ; Sandor, Victor (Array BioPharma Inc, Boulder, CO) ; Schellens, Jan H.M. (Utrecht University, Utrecht, the Netherlands) ; Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; VHIR Vall d'Hebron Institut de Recerca
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469  
3.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, T (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D C (The West Clinic, Memphis, USA) ; Obermannová, R (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G (St. Laszlo Hospital, Budapest, Hungary) ; Prausová, J (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; Garcia-Carbonero, R (Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain) ; Ciuleanu, T (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, P (Hospital General Universitario Gregorio Marañón) ; Cohn, A L (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E (Univ Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ; Yamazaki, K (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, S (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ; Kim, T W (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A (Mayo Clinic, Phoenix, USA) ; O'Connor, J (Instituto Alexander Fleming, Buenos Aires, Argentina) ; Taieb, J (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S R (Eli Lilly and Company, Indianapolis, USA) ; Hozak, R R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, J (Universitat Autònoma de Barcelona. Departament de Medicina) ; VHIO Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
4.
9 p, 325.6 KB Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study / Van Cutsem, E (Division of Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ; Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ; Lenz, H J (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ; Lonardi, S (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ; Falcone, A (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ; Limón, M L (Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain) ; Saunders, M (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ; Sobrero, A (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ; Park, Y S (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ; Ferreiro, R (Department of Clinical Oncology, Ramón y Cajal Hospital, Madrid, Spain) ; Hong, Y S (Department of Oncology, Asan Medical Center, Seoul, South Korea) ; Tomasek, J (Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic) ; Taniguchi, H (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ; Ciardiello, F (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ; Stoehr, J (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ; Oum'Hamed, Z (Boehringer Ingelheim France S.A.S, Reims, France) ; Vlassak, S (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ; Studeny, M (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ; Argiles, G (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963  
5.
8 p, 500.4 KB Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer / Siena, S (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; Sartore-Bianchi, A (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; Garcia-Carbonero, R (Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO, CIBERONC, Universidad Complutense, Madrid, Spain) ; Karthaus, M (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ; Smith, D (Department of Gastroenterology, University Hospital of Bordeaux, Hopital Haut Levaeque, Bordeaux, France) ; Tabernero, J (Universitat Autònoma de Barcelona) ; Van Cutsem, E (KU Leuven, Leuven, Belgium) ; Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ; Boedigheimer, M (Amgen Inc., Thousand Oaks, CA, USA) ; Ang, A (Amgen Inc., Thousand Oaks, CA, USA) ; Twomey, B (Amgen Inc., Thousand Oaks, CA, USA) ; Bach, B A (Amgen Inc., Thousand Oaks, CA, USA) ; Jung, A S (Amgen Inc., Thousand Oaks, CA, USA) ; Bardelli, A (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126  
6.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, J (Hospital Universitari Vall d'Hebron) ; Hozak, R R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, T (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A L (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R (Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic) ; Bodoky, G (Oncology, Szent László Hospital, Budapest, Hungary) ; Garcia-Carbonero, R (CIBERONC, Universidad Complutense, Madrid, Spain) ; Ciuleanu, T -E (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D C (Oncology, West Clinic, Memphis, USA) ; Prausová, J (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ; Siegel, R W (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R J (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, S A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, D (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  
7.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven and KU Leuven) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre/i+12) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (Antwerp University Hospital) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J (Dana-Farber Cancer Institute) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO Open, Vol. 2 (november 2017)  
8.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Czech Republic)) ; Van Cutsem, E. (KU Leuven. University Hospitals Leuven (Belgium)) ; Yoshino, T. (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hungary)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; Garcia-Carbonero, R. (Hospital Universitario Doce de Octubre) ; Ciuleanu, T. (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Marañón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, S. (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  
9.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Cervantes, A (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Roselló, Susana (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E (University Hospitals Gasthuisberg and KU Leuven) ; Tejpar, S (University Hospitals Gasthuisberg and KU Leuven) ; Prenen, H (University Hospitals Gasthuisberg and KU Leuven) ; Martinelli, E (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O (Merck KGaA) ; Ciardiello, F (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.